Development of The Lee Symptom Scale-Skin Sclerosis (LSS-Scl) for chronic GVHD-associated sclerosis Journal: Blood Published: 2025-01-15 DOI: 10.1182/blood.2024027334 Affiliations: 6 Authors: 5 Go ...

Additionally, 56% (95% CI, 44-67) of patients achieved at least a 7-point improvement in the modified Lee Symptom Scale score.

The trial also met a key exploratory endpoint, with a majority (56%) of patients achieving a ≥7-point improvement in the modified Lee Symptom Scale (mLSS) score.

Following the use of ruxolitinib for a median of 11 months, PR in skin and/or joints was noted in 49% (95% CI, 34 to 64) at 6 months, with 45% having joint and fascia response and 19% having skin ...